Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration

ATG for cord blood transplant: yes or no?

(2014) K. K. Ballen   BLOOD

Host Lymphocyte Depletion as a Strategy to Facilitate Early Full Donor Chimerism after Reduced-Intensity Allogeneic Stem Cell Transplantation

(2013) Rachel B. Salit et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine

(2012) Je-Hwan Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients

(2011) Jeannine S. McCune et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation

(2010) J R Long-Boyle et al.   BONE MARROW TRANSPLANTATION

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure

(2010) Antonin Schmitt et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies

(2009) Katarina Le Blanc et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients

(2009) D. H. Salinger et al.   CLINICAL CANCER RESEARCH

Personalized Dosing of Cyclophosphamide in the Total Body Irradiation–Cyclophosphamide Conditioning Regimen: A Phase II Trial in Patients With Hematologic Malignancy

(2009) JS McCune et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Busulfan in hematopoietic stem cell transplant setting

(2009) Jeannine S McCune et al.   Expert Opinion on Drug Metabolism & Toxicology

Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide

(2008) Christopher N. Bredeson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS

(2008) Borje S. Andersson et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

(2008) Erica L. Woodahl et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Intracellular disposition of fludarabine triphosphate in human natural killer cells

(2008) Erica L. Woodahl et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A tool for neutrophil guided dose adaptation in chemotherapy

(2008) Johan E. Wallin et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE